Competition Concerns in Fertility Clinic Pricing

Introduction

Fertility treatment markets—including IVF, IUI, egg freezing, embryo storage, donor programmes, fertility diagnostics and related laboratory services—raise distinctive competition concerns because patients often face high prices, limited ability to compare clinics, information asymmetry, emotionally sensitive decision-making, and substantial switching costs.

Competition law does not ordinarily prohibit a fertility clinic from charging a high price merely because the price is high. The principal concern arises where pricing is connected with collusion, exclusionary conduct, misleading price representations, tying/bundling, discriminatory access, or market concentration.

Recent enforcement illustrates the point. The Australian Competition and Consumer Commission (ACCC) specifically treated competition between low-cost IVF providers as capable of exerting downward pressure on IVF prices. The UK's Competition and Markets Authority (CMA), meanwhile, has identified difficulty in comparing headline IVF prices because packages may exclude important treatment components.

1. Relevant Competition Law Issues

A. Price Fixing Between Fertility Clinics

The clearest competition concern would arise if competing fertility clinics agreed upon:

• IVF package prices;
• consultation charges;
• embryo-storage fees;
• egg-freezing charges;
• donor compensation;
• laboratory charges;
• medication mark-ups;
• cancellation fees; or
• minimum or maximum prices.

An agreement between independent clinics to maintain particular prices can constitute horizontal price fixing.

The fact that fertility treatment involves medical and ethical considerations does not automatically immunise competitors from competition law.

Example

Suppose five IVF clinics in a city agree:

"No clinic will advertise a complete IVF cycle below ₹2,50,000."

Such an agreement could eliminate price competition even though each clinic remains independently owned.

2. Excessive or Exploitative Pricing

A clinic possessing substantial market power may potentially raise competition-law concerns if its pricing constitutes an abuse of dominance under the applicable jurisdiction's law.

However, high IVF prices alone are not automatically unlawful.

A competition authority would normally need to establish matters such as:

1. the relevant product market;
2. the geographic market;
3. dominance or substantial market power;
4. the competitive significance of the pricing conduct; and
5. where the jurisdiction recognises excessive pricing as an abuse, that the legal test for excessive pricing is satisfied.

This distinction is important because IVF is expensive to provide. Clinics incur costs relating to:

• embryologists;
• reproductive specialists;
• laboratories;
• cryopreservation;
• regulatory compliance;
• equipment;
• pharmaceuticals;
• genetic testing;
• quality-control systems; and
• facilities.

Therefore, cost-reflective pricing should not be confused with excessive pricing.

3. Misleading "Low-Cost IVF" Pricing

One of the most important practical issues is the difference between:

headline price and actual treatment price.

For example:

"IVF from ₹50,000"

may appear inexpensive but could exclude:

• consultation;
• ovarian stimulation;
• fertility medicines;
• anaesthesia;
• egg retrieval;
• embryology;
• ICSI;
• embryo transfer;
• cryopreservation;
• storage;
• genetic testing; and
• additional consultations.

The UK CMA has specifically examined fertility-clinic pricing information and found continuing difficulties for patients attempting to compare the cost of treatment across clinics.

The CMA's earlier fertility-sector review also identified unclear price information and misleading success-rate advertising as consumer-law concerns.

Thus, consumer-protection law and competition law may overlap, although misleading pricing is not necessarily an antitrust violation.

4. Bundling and Tying

A dominant fertility clinic may raise competition concerns by requiring patients to purchase additional services together with IVF.

Potential examples include:

• IVF + mandatory genetic testing;
• IVF + mandatory medication packages;
• IVF + mandatory embryo storage;
• IVF + mandatory counselling;
• IVF + proprietary laboratory services;
• fertility consultation + compulsory diagnostic package.

Bundling becomes particularly significant where the clinic possesses market power in one service and uses that power to foreclose competitors in another.

Competition analysis

Authorities may ask:

• Are the products genuinely separate?
• Is the bundle compulsory?
• Are independent alternatives available?
• Does the clinic possess market power?
• Does the practice foreclose competing providers?
• Are there legitimate medical or safety reasons for integration?

A medically justified package is different from a commercially imposed bundle designed to exclude competing providers.

5. Loyalty Discounts and Package Discounts

Fertility clinics may offer:

• multi-cycle discounts;
• annual fertility plans;
• membership programmes;
• "three-cycle IVF" packages;
• discounts for purchasing multiple services;
• financing-linked discounts.

Discounting is generally pro-competitive. However, where a dominant clinic uses loyalty rebates or exclusivity arrangements to prevent patients, doctors or referral networks from using competing clinics, an exclusionary-abuse theory may arise.

6. Exclusivity Arrangements With Fertility Specialists

Fertility clinics often depend upon highly specialised doctors and embryologists.

Exclusive arrangements could therefore have competitive significance.

For example:

Clinic A requires a leading fertility specialist not to provide IVF services to any competing clinic within a particular geographic area.

The concern becomes stronger where:

• the specialist is particularly important to patient choice;
• there are few qualified specialists;
• entry by competing clinics is difficult;
• the restriction lasts for a long period; and
• the arrangement substantially limits competing clinics' access to essential personnel.

The Australian fertility-merger litigation specifically identified specialist recruitment and restraint-of-trade clauses as potential barriers to entry.

7. Referral-Source Exclusivity

Fertility clinics may obtain patients through:

• gynaecologists;
• hospitals;
• diagnostic laboratories;
• insurance providers;
• fertility counsellors;
• digital platforms;
• employers.

Competition concerns can arise if a dominant clinic enters exclusive arrangements that prevent rival clinics from accessing important referral channels.

The analysis would depend heavily upon the clinic's market position and the actual foreclosure effect.

8. Vertical Integration With Fertility Laboratories

A clinic may operate its own:

• IVF laboratory;
• genetic-testing laboratory;
• sperm bank;
• egg bank;
• embryo-storage facility.

Vertical integration is not inherently unlawful.

But competition concerns could arise where a dominant clinic controls an important input and refuses or discriminates against competing clinics' access to it.

For example:

A dominant fertility laboratory provides embryo-testing services to its affiliated clinic but refuses access to independent clinics without objective justification.

This could potentially raise refusal-to-deal, discrimination or vertical foreclosure concerns.

9. Market Concentration and Fertility-Clinic Mergers

This is one of the most significant documented competition issues in the fertility sector.

If two major IVF providers merge, the authority may investigate whether the transaction will:

• eliminate a close competitor;
• increase concentration;
• reduce low-cost alternatives;
• increase prices;
• reduce patient choice;
• reduce innovation; or
• weaken bargaining options for patients.

The Australian Virtus–Adora matter provides an especially important example.

10. Case Law

1. ACCC v IVF Finance Pty Ltd (No 2) [2021] FCA 1295 — Australia

This is one of the most directly relevant fertility-sector competition cases.

The ACCC sought an interlocutory injunction preventing IVF Finance/Virtus from acquiring Adora Fertility. The ACCC alleged that the acquisition would substantially lessen competition under s 50 of the Competition and Consumer Act 2010.

The Federal Court granted the interlocutory injunction after finding a prima facie case concerning the proposed acquisition.

The ACCC's concerns included:

• increased concentration;
• elimination of competition between Virtus and Adora;
• reduced choice;
• potential increases in IVF prices; and
• barriers to entry.

Particularly important was evidence concerning Adora's low-cost fertility model, which was considered an important competitive constraint on other providers.

Principle

A merger involving fertility clinics can raise serious competition concerns where it removes an important low-price competitor from a concentrated local market.

2. Virtus Health Ltd / Adora Fertility — ACCC Merger Review and Abandonment (2021)

Although the transaction did not proceed to a final substantive merger judgment, the ACCC's enforcement action is highly significant.

The ACCC stated that Adora had been a vigorous competitor that drove down IVF prices through a low-cost model.

Virtus subsequently abandoned the proposed acquisition.

Principle

Competition authorities may treat the loss of a maverick or low-cost fertility provider as particularly significant because its competitive effect may be greater than its raw market share suggests.

3. Liverpool Partners Pty Ltd / Genea Ltd — ACCC, 2022

The ACCC subsequently examined another fertility-sector acquisition involving Adora and Genea.

The relevant markets involved fertility services, including IVF, in:

• Perth;
• Sydney; and
• Melbourne.

The ACCC did not oppose the acquisition after concluding that the transaction was not likely to substantially lessen competition. It considered the availability of other low-cost and full-service providers and the differentiation between Adora and Genea.

Principle

A fertility merger is not automatically problematic merely because the parties overlap. Authorities examine:

• closeness of competition;
• market concentration;
• differentiated business models;
• alternative suppliers;
• entry conditions; and
• likely competitive effects.

4. Monash IVF Group Ltd / Fertility North Holdings Pty Ltd — ACCC

The ACCC also examined Monash IVF's proposed acquisition of Fertility North in Perth.

The review focused on:

• overlap in fertility services;
• closeness of competition;
• potential entry;
• market structure; and
• whether the acquirer could materially alter its offerings after the acquisition.

The ACCC ultimately concluded that the transaction was not likely to substantially lessen competition.

Principle

Competition assessment in fertility markets is substantially localised. A merger may be problematic in one metropolitan area but not necessarily in another, depending upon available competitors and entry conditions.

5. In Re: Sabine S. v Mitera Hospital, Case No. 17 of 2024 — CCI, India

This is particularly important for Indian fertility-clinic pricing.

The informant alleged that Mitera Hospital, which specialised in infertility care, made statements concerning the cost of IVF treatment on YouTube.

The complaint alleged that statements concerning IVF pricing could prejudice hospitals offering affordable infertility treatment and potentially constitute abuse of dominance under Section 4 of the Competition Act, 2002.

The CCI closed the matter under Section 26(2), concluding that the allegations concerning misinformation/misstatements about IVF treatment costs did not fall within the Competition Act on the facts presented.

Principle

This case demonstrates an important boundary:

A dispute concerning misleading or inaccurate statements about IVF prices does not automatically become an abuse-of-dominance case.

There must be conduct falling within the substantive competition provisions.

6. Kamakahi v. American Society for Reproductive Medicine — U.S.

This case is particularly interesting because it involved the fertility industry itself, although the competition issue concerned the procurement side rather than patient pricing.

The litigation involved allegations of coordination among fertility clinics and donor agencies concerning compensation paid to women supplying human eggs.

The alleged conduct involved coordinated efforts to suppress egg-donor compensation. The case therefore illustrates the application of antitrust principles to fertility-sector price coordination, even though the affected price was an input price rather than the IVF price paid by patients.

Principle

Competition law protects competition not only in the price paid by patients but also in upstream fertility markets, including markets involving reproductive inputs.

7. Arizona v. Maricopa County Medical Society, 457 U.S. 332 (1982)

This is an important analogous healthcare pricing precedent.

Competing physicians agreed upon maximum fees for medical services supplied to particular insured patients.

The U.S. Supreme Court treated the arrangement as price fixing under §1 of the Sherman Act.

Application to fertility clinics

If competing IVF clinics similarly agreed:

"We will not charge less than ₹X for an IVF cycle,"

the arrangement could raise the same fundamental horizontal price-fixing concern.

The medical nature of the service does not itself transform competitors' agreement on prices into legitimate independent pricing.

8. FTC v. Phoebe Putney Health System, Inc., 568 U.S. 216 (2013)

This U.S. Supreme Court case concerned hospital consolidation.

A proposed acquisition would have effectively consolidated two hospitals in a local market. The FTC challenged the transaction because of its potential effect on competition.

The Supreme Court rejected the argument that general governmental powers automatically immunised the transaction from antitrust scrutiny.

Application to fertility clinics

The case is relevant where fertility clinics operate within larger hospital systems or public healthcare structures.

It demonstrates that:

• healthcare consolidation can attract antitrust scrutiny;
• regulatory status does not automatically eliminate competition-law concerns; and
• market concentration must still be considered.

11. Pricing Transparency as a Competition-Related Concern

The fertility sector has a special problem: the nominal price is often not the economically relevant price.

A patient comparing:

cannot necessarily conclude that Clinic A is actually cheaper.

This can weaken normal competitive forces because consumers cannot accurately compare competing offers.

The CMA has specifically recognised the difficulty patients face in comparing IVF treatment prices across clinics and has examined ways of improving price information.

12. Success-Rate Advertising and Pricing Competition

Price competition can also be distorted by claims concerning success rates.

A clinic might advertise:

"Highest IVF success rate at the lowest price."

If the success-rate calculation uses a different denominator, patient population or outcome measure from competing clinics, the comparison can give patients an inaccurate impression of relative value.

The ACCC investigated IVF clinics' success-rate representations and found that some comparisons did not adequately explain the underlying data.

This matters competitively because misleading quality claims can influence patients' willingness to pay and reduce effective price competition.

13. Relevant Market Definition

A competition authority may distinguish among:

Product markets

• IVF;
• IUI;
• fertility preservation;
• egg freezing;
• sperm banking;
• embryo storage;
• donor programmes;
• genetic testing;
• fertility diagnostics.

It may also examine whether:

low-cost IVF and premium/full-service IVF

belong to the same market.

The Australian ACCC has assessed fertility services, including IVF, on a metropolitan basis, while recognising that the precise product and geographic market need not always be conclusively determined if the transaction is not problematic on either plausible definition.

14. Geographic Market

Fertility markets are often local or metropolitan because patients consider:

• travelling distance;
• frequency of appointments;
• availability of specialists;
• laboratory location;
• egg retrieval facilities;
• embryo-transfer facilities;
• emergency access;
• doctor reputation.

Therefore, national market shares may conceal substantial local concentration.

The Virtus–Adora case demonstrates this clearly: the ACCC focused heavily upon competition in Brisbane and Melbourne.

15. Barriers to Entry

Potential barriers include:

1. high capital expenditure;
2. IVF laboratories;
3. specialised medical personnel;
4. embryologists;
5. regulatory approvals;
6. reputation-building;
7. patient referral networks;
8. economies of scale;
9. advertising and marketing expenditure;
10. restrictive covenants involving specialists.

The Federal Court evidence in the IVF Finance litigation specifically identified establishment costs, laboratories, qualified specialists, regulation, specialist restraints and the time required to achieve economies of scale as potential entry issues.

These barriers can make a concentrated fertility market more vulnerable to price increases following a merger.

16. Competition Concerns in Fertility Clinic Pricing — Summary Table

17. Indian Competition Act Perspective

For India, the principal provisions are:

Section 3

Prohibits agreements that cause or are likely to cause an appreciable adverse effect on competition.

Particularly relevant to:

• IVF price fixing;
• market-sharing;
• output restrictions;
• bid coordination;
• agreements between competing clinics.

Section 4

Concerns abuse of dominant position.

Potentially relevant conduct includes:

• unfair or discriminatory conditions;
• unfair or discriminatory prices;
• denial of market access;
• tying;
• leveraging dominance from one market into another.

However, dominance itself is not prohibited; abuse of dominance is.

The Mitera Hospital matter illustrates the CCI's cautious approach to allegations concerning IVF pricing where the alleged conduct did not fall within the Competition Act.

Sections 5 and 6

These provisions govern combinations and become relevant where major fertility-clinic groups acquire competitors.

18. Compliance Measures for Fertility Clinics

Fertility providers should maintain:

Independent pricing

Each clinic should independently determine:

• IVF prices;
• discounts;
• consultation fees;
• laboratory charges;
• storage fees.

Transparent packages

Clearly identify:

• what is included;
• what is excluded;
• medication costs;
• additional procedures;
• storage charges;
• cancellation/refund terms.

No competitor coordination

Clinics should avoid exchanging competitively sensitive information concerning:

• current prices;
• planned price increases;
• discounts;
• margins;
• capacity;
• strategic plans.

Merger review

Acquisitions should be assessed for:

• local market concentration;
• closeness of competition;
• loss of low-cost competitors;
• entry barriers;
• specialist access;
• patient switching possibilities.

Advertising compliance

Success rates and price claims should use:

• accurate data;
• consistent definitions;
• meaningful denominators;
• clear qualifications.

Conclusion

Competition concerns in fertility-clinic pricing extend considerably beyond the simple question of whether IVF treatment is expensive. The principal legal issues concern how prices are established, whether competitors coordinate, whether dominant providers exclude rivals, whether patients can meaningfully compare prices, and whether mergers eliminate important competitive constraints.

The fertility-specific cases are particularly instructive. ACCC v IVF Finance (No 2) demonstrates the significance of concentration and low-cost IVF competition; Liverpool Partners/Genea and Monash IVF/Fertility North show that authorities examine the precise competitive structure of individual metropolitan markets; Sabine S. v Mitera Hospital illustrates the limits of applying competition law to pricing-related statements; and Kamakahi demonstrates that antitrust concerns can arise within upstream reproductive markets as well. These can be supplemented by broader healthcare precedents such as Arizona v Maricopa County Medical Society on price fixing and FTC v Phoebe Putney on healthcare consolidation.